Ads
related to: monoclonal antibody treatment prostate cancer bone broth- Second Opinion
In Need of a Second Opinion?
Our Cancer Answer Line Can Help
- Schedule an Appointment
Schedule an Appointment Today
Call our Cancer Answer Line
- Prostate Cancer Treatment
Download our Prostate Cancer Guide
Find Prostate Cancer Treatments
- Virtual Second Opinions
Get Peace of Mind from Home.
Review Your Diagnosis & Treatment.
- Second Opinion
Search results
Results from the WOW.Com Content Network
Rosmantuzumab (INN; [1] development code OMP-131R10) is a humanized monoclonal antibody designed for the treatment of cancer. [ 2 ] [ 3 ] [ 4 ] This drug was developed by OncoMed Pharmaceuticals.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
It binds to the epithelial cell adhesion molecule (EpCAM - CD326), with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen. [1] Adecatumumab has been used in clinical studies of treatment in colorectal, prostate [2] and breast cancers. [3] Phase II results were published ...
It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the ligand IGF-1 and subsequent activation of PI3K / AKT signaling pathway.
Anti-cancer monoclonal antibodies can be targeted against malignant cells by several mechanisms. Ramucirumab is a recombinant human monoclonal antibody and is used in the treatment of advanced malignancies. [18] In childhood lymphoma, phase I and II studies have found a positive effect of using antibody therapy. [19]
Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. [1] Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators. This drug was developed by MacroGenics, Inc.
Ads
related to: monoclonal antibody treatment prostate cancer bone broth